Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 19/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021382 | 0.90 | OPRM1 (1.00) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL4022754 | 0.86 | OPRM1 (0.82) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL29893344 | 0.86 | OPRL1 (0.78) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL17158180 | 0.81 | OPRM1 (0.67) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL17158179 | 0.81 | OPRM1 (0.67) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL17158182 | 0.81 | OPRM1 (0.67) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20512444 | 0.77 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL28914563 | 0.77 | OPRM1 (0.69) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL10476540 | 0.75 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL3208044 | 0.75 | OPRM1 (0.68) | OPRM1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406858-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008370-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | claimed |
| EP-4739706-A1 | METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE | CSL Innovation Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583929-B2 | Method of treating acute respiratory distress syndrome | CSL Innovation Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-20260061050-A1 | METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE | CSL Innovation Pty Ltd (AU) | 2026-03-05 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| US-12357689-B2 | Methods of treating or preventing a cardiovascular system complication of sickle cell disease with an anti-G-CSFR antibody | CSL Innovation Pty Ltd (AU) | 2025-07-15 | — | — | US | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| WO-2022133519-A1 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL Innovation Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| EP-1406858-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | GRUENENTHAL GMBH (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7183436-B2 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| EP-1560806-B1 | 4-ALKYL/4-ALKENYL/4-ALKYNYL METHYL/-1-ARYLCYCLOHEXYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20040236104-A1 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1406858-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003008370-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | disclosed |
| US-4366172-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061050-A1 | METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE | CSF3R, MPO, CD69 | OPRM1 907/4885OPRL1 1090/4885OPRK1 1576/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRL1 4863/4885OPRK1 2862/4885 |
| US-20040236104-A1 | Substituted 4-aminocyclohexanols | CNR2, OPRK1, OPRL1 | OPRM1 7/4885OPRL1 3/4885OPRK1 2/4885 |
| US-12583929-B2 | Method of treating acute respiratory distress syndrome | CSF3R, CSF1R, FGB | OPRM1 648/4885OPRL1 463/4885OPRK1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.